Spigelman (ucla) - mcsp- exploratory chemistry (EC)
Ended Awarded Last action
- Contract number
- 75N95023F00003
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,981,927
Award facts
- Opportunity
-
- TORFPNIHNINDS2303 Solicitation number
- Contract value 57% obligated
-
- $1,981,926.84 Current, with exercised options
- $3,496,305.44 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $1,319,807 | |
| Original award | $662,120 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency, to Curia Global Inc. (doing business as Amri), a for-profit manufacturer of goods. The $3,496,305.44 contract supports "SPIGELMAN (UCLA) - MCSP- EXPLORATORY CHEMISTRY (EC)" activities, which likely include early-stage drug discovery and development services such as medicinal chemistry, ADME testing, and scale-up synthesis. This award is part of the Medicinal Chemistry Support Program for Therapeutic Development (MCSP), an IDIQ contract vehicle used by NINDS and other NIH institutes to advance research across various therapeutic areas, including neurology, infectious diseases, and substance abuse. No set-aside designation was used for this contract. Curia has extensive experience supporting federal agencies through prime and subcontract awards, leveraging its capabilities in pharmaceutical R&D, manufacturing, and pandemic response.
Quick answers
Who was awarded contract 75N95023F00003?
75N95023F00003 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on August 18, 2023.
How much is contract 75N95023F00003 worth?
The government has obligated $1,981,927 on 75N95023F00003. Its potential value, with all options, is $3,496,305.
Which agency awarded contract 75N95023F00003?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95023F00003, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95023F00003 an order under another contract?
Yes. 75N95023F00003 is a delivery order under HHSN271201800001I, an indefinite delivery contract.
Was contract 75N95023F00003 competed?
The extent of competition for 75N95023F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award